A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
This study plans to learn more about an investigational drug called ENMD-2076 and whether it can help patients with previously treated breast cancer.
Description
This study plans to learn more about an investigational drug called ENMD-2076 and whether it can help patients with previously treated breast cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
26 Apr 2024.
Study ID: 1207009094
